Corticosteroid-induced low immunoglobulin levels in multiple sclerosis - A confounding factor

被引:1
作者
Bonnan, Mickael [1 ]
Courtade, Henri [2 ]
Debeugny, Stephane [3 ]
机构
[1] Hop Delafontaine, Serv neurol, F-93200 St Denis, France
[2] Ctr Hosp Pau, Lab Biol Med, Pau, France
[3] Ctr Hosp Pau, Dept Informat Med, Pau, France
关键词
Multiple sclerosis; Immunoglobulin m; Immunoglobulin g; Disease-modifying therapies; Rituximab; Fingolimod; Natalizumab; Fumarate; Teriflunomide; RHEUMATOID-ARTHRITIS; LONG-TERM; RITUXIMAB; HYPOGAMMAGLOBULINEMIA; IGG; SAFETY;
D O I
10.1016/j.msard.2023.105039
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Changes in immunoglobulin (Ig) levels may occur in association with various drugs targeting immunity, including those used to treat multiple sclerosis (MS). However, influence of high-dose corticosteroids (CS) is poorly described. Objective: To describe influence of disease-modifying drugs (DMD) and CS on the Ig levels. Methods: Monocentric retrospective study examining changes in Ig levels in relation with CS intake in a series of 304 consecutive MS patients (and 1204 samples) followed or hospitalized for 7 years in a single centre. Ig levels are routinely collected in MS patients followed in our centre. Results: IgG levels were significantly lower in MS patients exposed to CS infusion during the last 24 months. IgG levels were also lower in DMD-treated patients exposed to CS. DMD-specific decrease of IgM levels was confirmed in interaction with CS. Conclusion: Stratification by CS exposure suggested that a decrease in Ig levels occurring during DMD treatment was strongly associated with CS infusion. The strong and persistent effect of CS on Ig levels could be a hidden variable and should be considered in further studies targeting Ig levels.
引用
收藏
页数:5
相关论文
共 28 条
  • [1] Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
    Bar-Or, Amit
    Calabresi, Peter A. J.
    Arnlod, Douglas
    Markowitz, Clyde
    Shafer, Stuart
    Kasper, Lloyd H.
    Waubant, Ernmanuelle
    Gazda, Suzanne
    Fox, Robert J.
    Panzara, Michael
    Sarkar, Neena
    Agarwal, Sunil
    Smith, Craig H.
    [J]. ANNALS OF NEUROLOGY, 2008, 63 (03) : 395 - 400
  • [2] Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study
    Boleto, G.
    Avouac, J.
    Wipff, J.
    Forien, M.
    Dougados, M.
    Roux, C.
    Kahan, A.
    Dieude, P.
    Allanore, Y.
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (02) : 149 - 154
  • [3] EFFECTS OF CORTICOSTEROIDS ON IMMUNITY IN MAN .1. DECREASED SERUM IGG CONCENTRATION CAUSED BY 3 OR 5 DAYS OF HIGH DOSES OF METHYLPREDNISOLONE
    BUTLER, WT
    ROSSEN, RD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (10) : 2629 - 2640
  • [4] Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience
    Evangelatos, Gerasimos
    Fragoulis, George E.
    Klavdianou, Kalliopi
    Moschopoulou, Melina
    Vassilopoulos, Dimitrios
    Iliopoulos, Alexios
    [J]. RHEUMATOLOGY, 2021, 60 (05) : 2375 - 2382
  • [5] Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities
    Gonzalez-Quintela, A.
    Alende, R.
    Gude, F.
    Campos, J.
    Rey, J.
    Meijide, L. M.
    Fernandez-Merino, C.
    Vidal, C.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 151 (01) : 42 - 50
  • [6] Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
    Hauser, S. L.
    Bar-Or, A.
    Comi, G.
    Giovannoni, G.
    Hartung, H. -P.
    Hemmer, B.
    Lublin, F.
    Montalban, X.
    Rammohan, K. W.
    Selmaj, K.
    Traboulsee, A.
    Wolinsky, J. S.
    Arnold, D. L.
    Klingelschmitt, G.
    Masterman, D.
    Fontoura, P.
    Belachew, S.
    Chin, P.
    Mairon, N.
    Garren, H.
    Kappos, L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03) : 221 - 234
  • [7] Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
    Hawker, Kathleen
    O'Connor, Paul
    Freedman, Mark S.
    Calabresi, Peter A.
    Antel, Jack
    Simon, Jack
    Hauser, Stephen
    Waubant, Emmanuelle
    Vollmer, Timothy
    Panitch, Hillel
    Zhang, Jiameng
    Chin, Peter
    Smith, Craig H.
    [J]. ANNALS OF NEUROLOGY, 2009, 66 (04) : 460 - 471
  • [8] Hoepner R., 2018, Clin. Transl. Neurosci., V1, P1
  • [9] HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH LONG-TERM, LOW-DOSE STEROID-THERAPY
    LEE, RJE
    FAY, AC
    [J]. POSTGRADUATE MEDICAL JOURNAL, 1985, 61 (716) : 523 - 524
  • [10] EFFECT OF HYDROCORTISONE ON IMMUNOGLOBULIN METABOLISM
    LEVY, AL
    WALDMANN, TA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1970, 49 (09) : 1679 - &